文献速递抗菌药物管理治疗药物监测与药物基因组学

奥利万星治疗骨髓炎:观察性研究的系统评价与Meta分析

Oritavancin for Treatment of Osteomyelitis: A Systematic Review and Meta-Analysis of Observational Studies.
PubMed 文献 · Pharmacotherapy · 2025-11-12

该系统评价与Meta分析纳入9项观察性研究共316例骨髓炎患者,评估奥利万星(ORI)的疗效与安全性。汇总临床成功率为81%(95%CI:76%-85%)。两项研究比较分析显示ORI优于对照药(达托霉素和达巴万星),OR比值比2.99(95%CI:0.86-10.36),但异质性显著(I2=80.2%,p=0.0247)。尽管FDA曾警告,未发现ORI治疗骨髓炎无效的证据。

要点

  • ORI治疗骨髓炎汇总临床成功率为81%(95%CI:76%-85%)
  • ORI对比达托霉素/达巴万星OR值为2.99(95%CI:0.86-10.36),异质性高
  • ORI给药频率低,可能为需每日肠外治疗者提供便利

核心结论

  • 尽管FDA曾警告,未发现ORI治疗骨髓炎无效的证据。
  • ORI低频给药方案可能较每日肠外治疗更便利,尤其针对MRSA和VRE等难治病原体。

研究设计与样本

  • 系统评价与Meta分析,检索7个数据库至2024年8月8日(PROSPERO注册号:CRD42025635473)。
  • 纳入9项观察性研究,共316例接受ORI治疗的骨髓炎患者。
  • 采用纽卡斯尔-渥太华量表评估研究质量,评分范围5/9至8/9。

主要发现

  • Meta分析显示汇总临床成功率为81%(95%CI:76%-85%)。
  • 两项研究比较分析得出OR值为2.99(95%CI:0.86-10.36),倾向于ORI优于对照药(达托霉素和达巴万星),但异质性显著(I2=80.2%,p=0.0247)。

关键数值与推荐

  • 临床成功定义为感染改善或痊愈,且无需额外革兰阳性抗菌药物、手术清创或截肢。

临床怎么用

  • ORI低频给药方案可能为骨髓炎患者提供便利,尤其针对MRSA和VRE等难治病原体。
  • 需进一步研究基于病原体敏感性的剂量优化策略,并建立适当的治疗药物监测方案。

局限性

  • 纳入研究均为观察性研究,多数在队列选择和可比性方面存在局限。
  • 比较分析异质性高(I2=80.2%),证据强度有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Osteomyelitis (OM) is a complex inflammatory bone infection typically requiring prolonged antibiotic therapy. Oritavancin (ORI), a long-acting lipoglycopeptide with activity against biofilm-embedded pathogens, has emerged as a potential treatment option despite previous US Food and Drug Administration (FDA) warnings against its use in OM. METHODS: We conducted a systematic review and meta-analysis of observational studies in seven databases through August 8, 2024 (PROSPERO registration: CRD42025635473) to evaluate the available evidence on ORI's efficacy and safety in OM. Clinical success was defined as the improvement or resolution of infection without requiring additional gram-positive antibiotics, surgical debridement, or amputation. Study quality was assessed using the Newcastle-Ottawa Scale. RESULTS: Our systematic review included nine observational studies comprising 316 patients with OM treated with ORI. Quality assessment using the Newcastle-Ottawa Scale revealed scores ranging from 5/9 to 8/9, with most studies demonstrating adequate outcome assessment but limitations in cohort selection and comparability. Meta-analysis demonstrated a pooled clinical success rate of 81% (95% CI: 76%-85%). Comparative analysis of two studies yielded an odds ratio of 2.99 (95% CI: 0.86-10.36) favoring ORI over comparators (daptomycin and dalbavancin), though with substantial heterogeneity (I2 = 80.2%, p = 0.0247). CONCLUSIONS: Despite previous warnings, we found no evidence of ineffectiveness with ORI for OM. ORI's infrequent dosing schedule may provide convenience over daily parenteral therapy, particularly for difficult-to-treat pathogens like MRSA and VRE. Further research is needed to optimize dosing strategies based on pathogen susceptibility and establish appropriate therapeutic drug monitoring protocols.

来源:Pharmacotherapy,查看原文。版权归原作者所有。

引用

  1. Krsak M, Klimpl D, Mueller SW, et al. Oritavancin for Treatment of Osteomyelitis: A Systematic Review and Meta-Analysis of Observational Studies. Pharmacotherapy. 2025. PMID: 41224240. doi:10.1002/phar.70072

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。